LLY Aug 2024 750.000 put

OPR - OPR Delayed price. Currency in USD

Add to watchlist

7.25

-1.06

(-12.76%)

As of 02:22PM EDT. Market open.

Loading interactive chart…

Yahoo Finance
Eli Lilly exec on weight-loss drugs: 'It's not just a flash in the pan'
Eli Lilly may be riding high on its diabetes and weight-loss treatments Mounjaro and Zepbound — which Wall Street estimates could net the company $13.5 billion in 2024 — but the success comes with ongoing criticism about pricing and access.
Investor's Business Daily
Eli Lilly Rises Again, As FDA Panel Mulls Biogen-Rivaling Alzheimer's Drug
Eli Lilly stock inched ahead Monday as a panel of advisors to the FDA gathered to discuss its experimental Alzheimer's treatment, donanemab.
Zacks
Biogen (BIIB) & Eisai's Leqembi sBLA Gets FDA Acceptance
FDA accepts Biogen's (BIIB) partner Eisai's sBLA for a maintenance intravenous dosing version of Alzheimer's drug Leqembi. The final FDA decision is expected on Jan 25, 2025.